High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk

Sigal Tavor*, Einam Rahamim, Nadav Sarid, Uri Rozovski, Lili Gibstein, Freddy Aviv, Ilya Kirsner, Elizabeth Naparstek

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk'. Together they form a unique fingerprint.

Keyphrases

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience